Table 2.
Tissue | Stage | Number of experiments, embryos analyzed | CFU-C/tissue/sorted cell fraction | |
---|---|---|---|---|
Venus− | Venus+ | |||
AGM | E9, 20-23sp | n = 2, 5 | 0.4 ± 0.4 | 8.0 ± 2.1 |
E10, 32-35sp | n = 2, 6 | 8.0 ± 2.3 | 69.0 ± 7.1 | |
VA+UA | E9, 20-23sp | n = 2, 5 | 0.8 ± 0.5 | 2.4 ± 1.0 |
E10, 32-35sp | n = 2, 6 | 7.0 ± 1.5 | 197.7 ± 36.9 | |
YS | E9, 20-23sp | n = 2, 5 | 270.0 ± 69.8 | 1020 ± 137.3 |
E10, 32-35sp | n = 2, 5 | 130.0 ± 25.5 | 1252.0 ± 156.0 | |
PL | E9, 20-23sp | n = 2, 5 | 4.0 ± 1.3 | 22.0 ± 2.5 |
E10, 32-35sp | n = 2, 6 | 14.5 ± 5.3 | 251.7 ± 32.4 | |
FL | E10, 32-35sp | n = 2, 6 | 20.5 ± 7.6 | 248.7 ± 75.2 |
Number of total CFU-C (mean ± SEM) per tissue per G2V embryo for the sorted Venus− and Venus+ cell fractions at E9 and E10.